Is BIOGF or DIVO a better dividend investment in 2026?

BIOGF currently yields 303.03% with a 5% 5-year dividend growth rate. DIVO yields 6.49% with 5% growth. The better choice depends on your goal: BIOGF offers higher current income.

What is the dividend yield difference between BIOGF and DIVO?

BIOGF has a forward dividend yield of 303.03% ($2.00/share annually). DIVO yields 6.49% ($2.91/share annually). The yield gap is 296.54 percentage points.

Home › Compare › BIOGF vs DIVO

BIOGF vs DIVO: Dividend Comparison 2026

BIOGF yields 303.03% · DIVO yields 6.49%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 BIOGF wins by $1619.96M in total portfolio value

INVESTMENT

TIME HORIZON10 years

BIOGF

● Live price

303.03%

Share price

$0.66

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$1619.99M

Annual income

$982,313,976.38

Full BIOGF calculator →

DIVO

● Live price

6.49%

Share price

$44.85

Annual div

$2.91

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.7K

Annual income

$981.68

Full DIVO calculator →

Portfolio growth — BIOGF vs DIVO

📍 BIOGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	BIOGF	DIVO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, BIOGF + DIVO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

BIOGF pays

DIVO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BIOGF

Annual income on $10K today (after 15% tax)

$25,757.58/yr

After 10yr DRIP, annual income (after tax)

$834,966,879.92/yr

DIVO

Annual income on $10K today (after 15% tax)

$552.00/yr

After 10yr DRIP, annual income (after tax)

$834.43/yr

At 15% tax rate, BIOGF beats the other by $834,966,045.50/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BIOGF + DIVO for your $10,000?

BIOGF: 50%DIVO: 50%

100% DIVO50/50100% BIOGF

Portfolio after 10yr

$810.01M

Annual income

$491,157,479.03/yr

Blended yield

60.64%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BIOGF buys

DIVO buys

No recent congressional trades found for BIOGF or DIVO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricBIOGFDIVO

Forward yield	303.03% ✓	6.49%
Annual dividend / share	$2.00	$2.91 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$1619.99M ✓	$30.7K
Annual income after 10y	$982,313,976.38 ✓	$981.68
Total dividends collected	$1556.25M ✓	$8.2K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: BIOGF vs DIVO ($10,000, DRIP)

Year	BIOGF Portfolio	BIOGF Income/yr	DIVO Portfolio	DIVO Income/yr	Gap
1← crossover	$41,003	$30,303.03	$11,349	$649.42	+$29.7K → BIOGF
2	$159,996	$116,123.00	$12,833	$688.83	+$147.2K → BIOGF
3	$594,671	$423,475.49	$14,459	$727.90	+$580.2K → BIOGF
4	$2,107,296	$1,470,997.14	$16,238	$766.49	+$2.09M → BIOGF
5	$7,126,460	$4,871,653.73	$18,179	$804.47	+$7.11M → BIOGF
6	$23,022,487	$15,397,174.28	$20,293	$841.71	+$23.00M → BIOGF
7	$71,121,500	$46,487,438.99	$22,591	$878.14	+$71.10M → BIOGF
8	$210,314,839	$134,214,834.84	$25,087	$913.65	+$210.29M → BIOGF
9	$595,961,579	$370,924,701.05	$27,791	$948.18	+$595.93M → BIOGF
10	$1,619,992,866	$982,313,976.38	$30,718	$981.68	+$1619.96M → BIOGF

BIOGF vs DIVO: Complete Analysis 2026

BIOGF — Stock

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.

Full BIOGF Calculator →

DIVO — ETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →

📬

Get this BIOGF vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BIOGF vs SCHD BIOGF vs JEPI BIOGF vs O BIOGF vs KO BIOGF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.